Role Of Measurable Residual Disease (Mrd) In Redefining Complete Response (Cr) In Elderly Patients With Acute Myeloid Leukemia (Aml): Results From The Pethema-Flugaza Phase Iii Clinical Trial

Background: Incidence of AML is highest among the elderly and the general outcome is poor as compared to young patients, even those who tolerate intensive induction chemotherapy and achieve morphological CR. However, the role of MRD in redefining CR in elderly AML remains poorly investigated due to the reluctance to treat them with intensive chemotherapy, the renewed interest in low-intensity therapy such as hypomethylating agents (HMA), and the lack of molecular MRD markers in most patients.